Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.

Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash. Eli Lilly on Monday said Orna, which is dedicated to engineering immune ...

Hims & Hers Health began advertising a $49 Ozempic pill lookalike last week -- then stopped. Novo Nordisk charges $149 for its own Wegovy pills. Lilly charges $299 for Zepbound shots. First, on Friday ...

Matthew Herper covers medical innovation — both its promise and its perils. Eli Lilly will pay up to $2.4 billion to acquire Orna Therapeutics, a biotechnology firm that is developing a technology to ...

As the 2026 Winter Olympics get underway in Italy this week, Eli Lilly—a partner of both Team USA and the Milan Cortina Games as a whole—is rolling out a new corporate campaign inspired by the event.

Eli Lilly’s stock closed 10.3% higher on Wednesday after the drug giant reported triple-digit growth of Zepbound and Mounjaro, its game-changing weight-loss and Type 2 diabetes drugs. That’s the third ...

Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...

Profit and revenue forecasts for 2026 well above Street view Lilly's Q4 profit and revenue exceed expectations Lilly's obesity drug Zepbound boosts sales despite price cuts Lilly's orforglipron pill ...

INDIANAPOLIS (AP) — INDIANAPOLIS (AP) — Eli Lilly and Co. (LLY) on Wednesday reported fourth-quarter net income of $6.64 billion. The Indianapolis-based company said it had net income of $7.39 per ...

Eli Lilly & Co. struck a deal worth more than $1.1 billion with German biotech Seamless Therapeutics GmbH to develop gene therapies for hearing loss. Closely-held Seamless will design a type of enzyme ...

Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...